28 juli 2009

Reve 21 & Dignitana: A Model for Japan - Sweden Collaboration

The Investment Office at Embassy of Sweden in Tokyo is the office in Japan of Invest in Sweden Agency (ISA). One of its core missions is to encourage Japanese companies to take advantage of the business opportunities in Sweden stemming from exciting new technology coming up through venture company spin offs from academic research at Swedish Universities.

Hans Rhodiner, Industrial Counsellor at Embassy of Sweden in Tokyo and head of ISA Japan, says that "the collaboration just established between Reve 21 and Dignitana AB is a model example of what we believe is a very successful way for a small Swedish venture company to get access to both capital and competence in Japan while at the same time providing a major Japanese company with an exciting new product and technology. It is a clear Win-Win situation".

Given this situation, its only natural that the announcement of this collaboration between Reve 21 and Dignitina AB will be officially announced at a press conference at Embassy of Sweden in Tokyo on July 28th from 3PM.


For further information please contact:

Hans Rhodiner, Industrial Counsellor at Embassy of Sweden in Tokyo
hans.rhodiner(snabel-a)isatokyo(punkt)org
+ 81 90 2768 8977
+ 81 3 5562 5014


Dignitana bedriver verksamhet inom området medicinteknik. Bolaget har utvecklat ett patenterat skalpkylningssystem som reducerar cytostatikarelaterat (cellgift) håravfall; DigniCap™. DigniCap™-systemet har sedan 1998 genomgått omfattande utvecklingsarbete och kliniska studier. Tusentals patienter är redan framgångsrikt behandlade med DigniCap™, som nu är redo för en internationell lansering.

Kontaktinformation

Tel: 046-16 30 90
Fax: 046-16 30 99
E-post: info(snabel-a)dignitana.com

Dignitana AB

Dignitana utvecklar ett patenterat skalpkylningssystem, DigniCap™, som reducerar håravfall vid cellgiftsbehandling. Dignitanas patenterade DigniCap™-system har vid kliniska studier uppvisat utmärkta vetenskapliga resultat, fler än åtta av tio behandlade patienter har fått behålla sitt hår i sådan utsträckning att användning av peruk inte varit nödvändig.